| Basics |
Xencor, Inc.
Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
|
| IPO Date: |
December 3, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$609.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.56 | 2.30%
|
| Avg Daily Range (30 D): |
$0.21 | 2.68%
|
| Avg Daily Range (90 D): |
$0.26 | 2.99%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.26M |
| Avg Daily Volume (30 D): |
.56M |
| Avg Daily Volume (90 D): |
.62M |
| Trade Size |
| Avg Trade Size (Sh.): |
68 |
| Avg Trade Size (Sh.) (30 D): |
65 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
3,002 |
| Avg Inst. Trade: |
$1.98M |
| Avg Inst. Trade (30 D): |
$1.01M |
| Avg Inst. Trade (90 D): |
$1.32M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.24M |
| Avg Closing Trade (30 D): |
$1.03M |
| Avg Closing Trade (90 D): |
$1.33M |
| Avg Closing Volume: |
85.08K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.41
|
$-.66
|
|
Diluted EPS
|
|
$-.41
|
$-.66
|
|
Revenue
|
$
|
$ 43.61M
|
$ 32.73M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -30.83M
|
$ -48.63M
|
|
Operating Income / Loss
|
$
|
$ -33.17M
|
$ -43.18M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 4.77M
|
$ -1.3M
|
|
PE Ratio
|
|
|
|
|
|
|
